{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:00:29Z","timestamp":1783720829876,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>JAVEMACS-D was an observational, retrospective study describing real-world characteristics, treatment patterns, and outcomes in patients with advanced urothelial carcinoma (aUC) treated with avelumab maintenance after first-line platinum-based chemotherapy (PBC) in Japan using a large claims database (Medical Data Vision). Between February 2021 and April 2023, 773 patients received avelumab maintenance; median age was 74\u00a0years, primary tumor site was bladder in 59.9% and renal pelvis\/ureter in 42.7%, and first-line PBC was cisplatin-gemcitabine in 61.3% and carboplatin-gemcitabine in 36.4%. Avelumab maintenance started in 2021 in 289 patients (37.4%) and in 2022 or later in 484 (62.6%). At data cutoff (October 2023), median follow-up was 19.3\u00a0months, and 22.0% of patients were still receiving avelumab. Among 394 patients (51.0%) who received second-line treatment, the most common was enfortumab vedotin (EV) in 47.0%. Median time to treatment failure (TTF; time from start of avelumab maintenance to discontinuation) was 4.5\u00a0months (95% CI 3.8\u20135.2). Median TTF2 (time from start of avelumab to discontinuation of subsequent treatment) was 10.1\u00a0months (95% CI 8.7\u201311.0). JAVEMACS-D represents the largest real-world dataset of avelumab maintenance therapy for aUC reported to date. Data provide insights about patient characteristics, treatment patterns, and outcomes within an evolving treatment landscape.<\/jats:p>","DOI":"10.1038\/s41598-025-25515-1","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:36:11Z","timestamp":1764081371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan"],"prefix":"10.1038","volume":"15","author":[{"given":"Takashi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"25515_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"25515_CR2","unstructured":"NCCN. Clinical Practice Guidelines in Oncology: Bladder Cancer v1 (2025)."},{"key":"25515_CR3","first-page":"1","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 1 (2020).","journal-title":"Med. Sci."},{"key":"25515_CR4","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"25515_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann. Oncol. 35, 485\u2013490 (2024).","journal-title":"Ann. Oncol."},{"key":"25515_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas, R. et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 81, 95\u2013103 (2022).","journal-title":"Eur. Urol."},{"key":"25515_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/iju.15362","volume":"31","author":"K Mori","year":"2024","unstructured":"Mori, K. et al. Summary of the clinical practice guidelines for upper tract urothelial carcinoma 2023 by the Japanese Urological Association. Int. J. Urol. 31, 194\u2013207 (2024).","journal-title":"Int. J. Urol."},{"key":"25515_CR8","unstructured":"Bavencio (avelumab). Prescribing Information (Japan). Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.  https:\/\/www.pmda.go.jp\/drugs\/2019\/P20191217003\/380079000_22900AMX00990_A100_1.pdf (2019)"},{"key":"25515_CR9","unstructured":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) receives new approvals in Japan for certain patients with non-small cell lung carcinoma (NSCLC) and radically unresectable urothelial carcinoma. https:\/\/www.merck.com\/news\/mercks-keytruda-pembrolizumab-receives-new-approvals-in-japan-for-certain-patients-with-non-small-cell-lung-carcinoma-nsclc-and-radically-unresectable-urothelial-carcinoma\/ (2024)."},{"key":"25515_CR10","unstructured":"Ono Pharma. Ono receives supplemental approval of opdivo\u00ae in combination with cisplatin and gemcitabine for treatment of unresectable urothelial carcinoma in Japan. https:\/\/www.ono-pharma.com\/en\/news\/20241227.html (2024)."},{"key":"25515_CR11","unstructured":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) approved in Japan for use in the treatment of patients with urothelial carcinoma that is unresectable with radical surgery who have progressed following cancer chemotherapy. https:\/\/www.merck.com\/news\/mercks-keytruda-pembrolizumab-approved-in-japan-for-use-in-the-treatment-of-patients-with-urothelial-carcinoma-that-is-unresectable-with-radical-surgery-who-have-progressed-following\/ (2018)."},{"key":"25515_CR12","unstructured":"Astellas Pharma. Japan\u2019s MHLW approves PADCEV\u00ae (enfortumab vedotin) for advanced urothelial cancer. https:\/\/www.astellas.com\/en\/news\/17206 (2021)."},{"key":"25515_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218\u20131230 (2020).","journal-title":"N. Engl. J. Med."},{"key":"25515_CR14","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles, T. et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up. J. Clin. Oncol. 41, 3486\u20133492 (2023).","journal-title":"J. Clin. Oncol."},{"key":"25515_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10147-021-02067-8","volume":"27","author":"Y Tomita","year":"2022","unstructured":"Tomita, Y. et al. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. Int. J. Clin. Oncol. 27, 383\u2013395 (2022).","journal-title":"Int. J. Clin. Oncol."},{"key":"25515_CR16","doi-asserted-by":"publisher","first-page":"e71264","DOI":"10.1002\/cam4.71264","volume":"14","author":"E Kikuchi","year":"2025","unstructured":"Kikuchi, E. et al. Real-world outcomes of avelumab maintenance therapy in patients with curatively unresectable urothelial carcinoma in Japan: results from the final analysis of postmarketing surveillance. Cancer Med. 14, e71264 (2025).","journal-title":"Cancer Med."},{"key":"25515_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","volume":"8","author":"P Barthelemy","year":"2025","unstructured":"Barthelemy, P. et al. Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in france: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment. Eur. Urol. Oncol. 8, 407\u2013416 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"25515_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","volume":"21","author":"DR Bakaloudi","year":"2023","unstructured":"Bakaloudi, D. R. et al. Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \u201creal world\u201d experience. Clin. Genitourin. Cancer 21, 584\u2013593 (2023).","journal-title":"Clin. Genitourin. Cancer"},{"key":"25515_CR19","first-page":"100068","volume":"5","author":"L Antonuzzo","year":"2024","unstructured":"Antonuzzo, L. et al. READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma. ESMO RWD DO 5, 100068 (2024).","journal-title":"ESMO RWD DO"},{"key":"25515_CR20","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.clgc.2024.102238","volume":"22","author":"P Grivas","year":"2024","unstructured":"Grivas, P. et al. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study. Clin. Genitourin. Cancer 22, 102238 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"25515_CR21","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.3390\/curroncol31090420","volume":"31","author":"HH Moon","year":"2024","unstructured":"Moon, H. H. et al. Real-world treatment patterns, sequencing, and outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in the United States. Curr. Oncol. 31, 5662\u20135676 (2024).","journal-title":"Curr. Oncol."},{"key":"25515_CR22","doi-asserted-by":"publisher","first-page":"1403120","DOI":"10.3389\/fonc.2024.1403120","volume":"14","author":"SH Park","year":"2024","unstructured":"Park, S. H. et al. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program. Front. Oncol. 14, 1403120 (2024).","journal-title":"Front. Oncol."},{"key":"25515_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/iju.15473","volume":"31","author":"E Kikuchi","year":"2024","unstructured":"Kikuchi, E. et al. J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan. Int. J. Urol. 31, 859\u2013867 (2024).","journal-title":"Int. J. Urol."},{"key":"25515_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s11523-024-01099-0","volume":"19","author":"O Fiala","year":"2024","unstructured":"Fiala, O. et al. Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: a retrospective data from the ARON-2EV study. Target Oncol. 19, 905\u2013915 (2024).","journal-title":"Target Oncol."},{"key":"25515_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2024.42.4_suppl.537","volume":"42","author":"A Nizam","year":"2024","unstructured":"Nizam, A. et al. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. J. Clin. Oncol. 42, 537 (2024).","journal-title":"J. Clin. Oncol."},{"key":"25515_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.esmoop.2025.104506","volume":"10","author":"S Gupta","year":"2025","unstructured":"Gupta, S. et al. Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients. ESMO Open 10, 1 (2025).","journal-title":"ESMO Open"},{"key":"25515_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/iju.15411","volume":"31","author":"Y Kita","year":"2024","unstructured":"Kita, Y. et al. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. Int. J. Urol. 31, 552\u2013559 (2024).","journal-title":"Int. J. Urol."},{"key":"25515_CR28","unstructured":"Bavencio (avelumab). Prescribing Information. EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA (2024)."},{"key":"25515_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.urolonc.2022.07.008","volume":"40","author":"A Hamada","year":"2022","unstructured":"Hamada, A. et al. Limited predictive impact of tumor size dynamics on further tumor shrinkage after 4 cycles of first-line chemotherapy in patients with advanced urothelial carcinoma. Urol. Oncol. 40, 540 (2022).","journal-title":"Urol. Oncol."},{"key":"25515_CR30","first-page":"1","volume":"1","author":"J Panian","year":"2024","unstructured":"Panian, J. et al. Efficacy of treatments after lenvatinib in patients with advanced renal cell carcinoma. Eur. Urol. Focus 1, 1 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"25515_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal, G. M. et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann. Oncol. 30, 830\u2013838 (2019).","journal-title":"Ann. Oncol."},{"key":"25515_CR32","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado, A. & Guddati, A. K. Clinical endpoints in oncology\u2014a primer. Am. J. Cancer Res. 11, 1121\u20131131 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"25515_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent, T. et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes 9, 175\u2013187 (2022).","journal-title":"Drugs Real World Outcomes"},{"key":"25515_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/03007995.2022.2096353","volume":"38","author":"M Shiota","year":"2022","unstructured":"Shiota, M., De Moor, R., Koroki, Y., Yu, D. Y. & Wu, D.B.-C. Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan. Curr. Med. Res. Opin. 38, 1351\u20131359 (2022).","journal-title":"Curr. Med. Res. Opin."},{"key":"25515_CR35","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1007\/s12325-023-02616-9","volume":"40","author":"H Hayashi","year":"2023","unstructured":"Hayashi, H., Nishio, M., Takahashi, M., Tsuchiya, H. & Kasahara-Kiritani, M. Real-world data about treatment outcomes for patients with EGFR-mutated NSCLC resistance to osimertinib and platinum-based chemotherapy. Adv. Ther. 40, 4545\u20134560 (2023).","journal-title":"Adv. Ther."},{"key":"25515_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15174227","volume":"15","author":"T Kawahara","year":"2023","unstructured":"Kawahara, T. et al. Administration of enfortumab vedotin after immune-checkpoint inhibitor and the prognosis in Japanese metastatic urothelial carcinoma: a large database study on enfortumab vedotin in metastatic urothelial carcinoma. Cancers 15, 1 (2023).","journal-title":"Cancers"},{"key":"25515_CR37","unstructured":"Astellas Pharma. Antibody-Drug Conjugate \"Padosev\u00ae for Intravenous Infusion 30 mg\" Launched in Japan. https:\/\/www.astellas.com\/jp\/news\/24736 (2021)."},{"key":"25515_CR38","doi-asserted-by":"publisher","first-page":"e16621","DOI":"10.1200\/JCO.2024.42.16_suppl.e16621","volume":"42","author":"KR Carson","year":"2024","unstructured":"Carson, K. R. et al. Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC) treated with avelumab first-line maintenance (1LM). J. Clin. Oncol. 42, e16621 (2024).","journal-title":"J. Clin. Oncol."},{"key":"25515_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg, J. E. et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann. Oncol. 34, 1047\u20131054 (2023).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25515-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:36:13Z","timestamp":1764081373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25515-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25515"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25515-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Kobayashi has participated in consulting or advisory roles for Astellas Pharma, AstraZeneca, Bayer, Chugai, Janssen, Medicaroid, MSD, and Nippon Kayaku; has participated in speakers bureau for Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Janssen, Kissei, Merck, MSD, Nippon Kayaku, Nippon Shinyaku, Ono Pharmaceutical, Pfizer, Sanofi, and Takeda; and has received institutional research funding from Astellas, AstraZeneca, Bayer, and Chugai. H. Kitamura has participated in consulting or advisory roles for Astellas, AstraZeneca, Bristol Myers Squibb, Chugai, Eisai, Ferring, J&J\/Janssen, Kissei Pharmaceutical, MSD, Pfizer, and Takeda; has participated in speakers bureaus for Astellas, AstraZeneca, Bristol Myers Squibb, J&J\/Janssen, Merck, MSD, Nippon Shinyaku, Sanofi, and Takeda; and has received institutional research funding from J&J\/Janssen. Y. Furukawa has nothing to disclose. M. Shono and T. Ito are employees of Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA. E. Kikuchi has participated in consulting or advisory roles for Astellas, AstraZeneca, Chugai, Ferring, Janssen, Merck, and MSD; has participated in speakers bureaus for Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Eisai, Janssen, Kyorin, Merck, MSD, Nippon Kayaku, and Takeda; and has received institutional research funding from Astellas, AstraZeneca, Bristol Myers Squibb, Chugai, Kyorin, Merck, MSD, and Nippon Kayaku.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the nonprofit organization MINS. Approval number: MINS-REC-240212.\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was registered on jRCT (Japan Registry of Clinical Trials). Registration number: jRCT1031240122.\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registration"}}],"article-number":"41773"}}